MEDICAMEQ Share Price Target 2035

CAGR-based price projection for Medicamen Biotech Limited (MEDICAMEQ) targeting 2035, derived from official NSE exchange closing prices.

Bear Case (17.4% CAGR)
Rs 1,471
2035 Target
Base Case (43.6% CAGR)
Rs 8,980
2035 Target
Bull Case (138.0% CAGR)
Rs 848,387
2035 Target

Current Market Snapshot

CMP: Rs 346.30
52W High: Rs 346.30
52W Low: Rs 219.88
1Y CAGR: 106.2%
3Y CAGR: 43.6%

Year-by-Year Price Projection

YearBear CaseBase CaseBull Case
2027 Rs 407 Rs 497 Rs 824
2028 Rs 478 Rs 714 Rs 1,962
2029 Rs 561 Rs 1,025 Rs 4,668
2030 Rs 659 Rs 1,472 Rs 11,111
2031 Rs 773 Rs 2,113 Rs 26,443
2032 Rs 908 Rs 3,034 Rs 62,933
2033 Rs 1,066 Rs 4,356 Rs 149,779
2034 Rs 1,252 Rs 6,255 Rs 356,470
2035 Rs 1,471 Rs 8,980 Rs 848,387

Other MEDICAMEQ Price Targets

2025 2026 2027 2028 2030 2040 2050

Frequently Asked Questions

What is the MEDICAMEQ share price target for 2035?

Based on historical growth analysis, the MEDICAMEQ share price target for 2035 ranges from Rs 1,471 (conservative) to Rs 8,980 (base case) to Rs 848,387 (optimistic). These projections are based on trailing CAGR and should not be treated as guaranteed outcomes.

What is the current share price of MEDICAMEQ?

The current market price of MEDICAMEQ (Medicamen Biotech Limited) is Rs 346.30. The 52-week high is Rs 346.30 and 52-week low is Rs 219.88.

Is MEDICAMEQ a good stock to buy for the long term?

Long-term investment decisions depend on individual risk tolerance, financial goals, and portfolio diversification. Examine the company's fundamentals, debt-to-equity ratio, promoter holding, and competitive positioning within its sector. BrokerLens provides data-driven analysis; consult a SEBI-registered financial advisor before investing.

What methodology does BrokerLens use for MEDICAMEQ price targets?

BrokerLens computes price targets using historical Compound Annual Growth Rate (CAGR) derived from official NSE closing prices. Three scenarios are modeled: Bear (conservative at 17.4% CAGR), Base (43.6% CAGR), and Bull (optimistic at 138.0% CAGR). These are statistical projections, not guaranteed forecasts.

Disclaimer: Share price targets on BrokerLens are statistical CAGR projections based on historical NSE closing prices. They are NOT guaranteed outcomes, investment advice, or analyst recommendations. Past performance does not guarantee future results. Consult a SEBI-registered investment advisor before making investment decisions. Mutual fund and equity investments are subject to market risks.